Veru (VERU)

• Market cap: $43.3M
• 1 day: -4.51%
• 5 days: -0.39%
• 1 month: -5.58%
• 3 months: -19.62%
• 6 months: 11.89%
• Year to date: 11.89%
• 1 year: -34.7%
• 5 years: -97%
• 10 years: -78.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Employees: 20